Squarepoint’s Akari Therapeutics AKTX Stock Holding History

Squarepoint’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-24	Closed	-$41K	–	2458
2020 Q2	$41K	Buy	+24	New	+$36.6K	﹤0.01%	2114

Other funds holding AKTX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OFW

Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return

UAS

United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Squarepoint's AKTX Position: Q3 2020 in Review

Squarepoint sold out of Akari Therapeutics (AKTX) in Q3 2020, closing a stake of 24 shares — an estimated $41K sold.

Squarepoint first reported a position in AKTX in Q2 2020 and held it in 1 quarter. The position peaked at $41K in Q2 2020. 12 funds tracked by Wall St. Rank hold AKTX as of Q3 2020.

Squarepoint reported no remaining Akari Therapeutics position as of Q3 2020 after selling out during the quarter.
Squarepoint sold 24 Akari Therapeutics shares in Q3 2020, an estimated $41K.
Squarepoint first reported a position in Akari Therapeutics in Q2 2020 and held it in 1 quarter.
Squarepoint's Akari Therapeutics position peaked at $41K in Q2 2020.
12 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2020.

Based on Squarepoint's 13F filing for Q3 2020, filed 16 Nov 2020.